{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:58:21Z","timestamp":1773201501640,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bone.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T10:51:09Z","timestamp":1529059869000},"page":"109-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-5818","authenticated-orcid":false,"given":"Ioannis","family":"Kyvernitakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Herbert","family":"Kann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Thomasius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Hars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10071","key":"10.1016\/j.bone.2018.06.007_bb0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","article-title":"The global burden of women's cancers: a grand challenge in global health","volume":"389","author":"Ginsburg","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2018.06.007_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.bone.2018.06.007_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/13697137.2014.929105","article-title":"Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer","volume":"18","author":"Kyvernitakis","year":"2015","journal-title":"Climacteric"},{"issue":"8","key":"10.1016\/j.bone.2018.06.007_bb0020","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bone.2018.06.007_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00198-014-2955-3","article-title":"Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy","volume":"26","author":"Kalder","year":"2015","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2018.06.007_bb0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-014-2860-7","article-title":"Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study","volume":"144","author":"Hadji","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.bone.2018.06.007_bb0035","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00198-013-2615-z","article-title":"Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study","volume":"25","author":"Hadji","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"14","key":"10.1016\/j.bone.2018.06.007_bb0040","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2018.06.007_bb0045","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan Gel","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bone.2018.06.007_bb0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.bone.2018.06.007_bb0055","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"10001","key":"10.1016\/j.bone.2018.06.007_bb0060","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.bone.2018.06.007_bb0065","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bone.2018.06.007_bb0070","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bone.2018.06.007_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/13697137.2014.984675","article-title":"Comparison of dual-energy X-ray absorptiometry with six quantitative ultrasonometry devices in women with hip fractures","volume":"18","author":"Hadji","year":"2015","journal-title":"Climacteric"},{"issue":"12","key":"10.1016\/j.bone.2018.06.007_bb0080","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bone.2018.06.007_bb0085","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9561","key":"10.1016\/j.bone.2018.06.007_bb0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bone.2018.06.007_bb0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Arimidex","year":"2008","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bone.2018.06.007_bb0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bone.2018.06.007_bb0105","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.bone.2018.06.007_bb0110","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bone.2018.06.007_bb0115","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat. Rev."},{"issue":"15","key":"10.1016\/j.bone.2018.06.007_bb0120","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.06.007_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-053014-103600","article-title":"Adjuvant bisphosphonates and breast Cancer survival","volume":"67","author":"Strobl","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bone.2018.06.007_bb0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-642-21892-7_3","article-title":"Bisphosphonates: prevention of bone metastases in breast cancer","volume":"192","author":"Gnant","year":"2012","journal-title":"Recent Results Cancer Res."},{"issue":"9","key":"10.1016\/j.bone.2018.06.007_bb0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218302394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218302394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:41:54Z","timestamp":1757612514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328218302394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":27,"alternative-id":["S8756328218302394"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2018.06.007","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}